Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection ...

Checkmate, which is a personalized smart shopping tool aimed at making it easy for users to discover brands, apply savings and manage their orders post-purchase, said it secured $5 million in a seed ...

Other Participants in the Round Include Kevin Johnson (former CEO of Ebates at Rakuten), f7 Ventures, Blackbird Ventures, Scribble Ventures, Hyper and Susa Ventures SAN FRANCISCO--(BUSINESS ...

This week, drug maker Bristol-Myers Squibb announced in a press release that the ongoing Phase 3 Checkmate-227 trial met its co-primary endpoint of progression-free survival with Opdivo plus Yervoy ...

Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC). Bristol Myer Squibb (BMS)’s recent immunotherapy success, ...

Opdivo demonstrates superior overall survival in this Phase 3 trial (PRINCETON, NJ, January 11, 2015) – Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 ...

SAN FRANCISCO--(BUSINESS WIRE)--Checkmate, a personalized smart shopping tool that makes it easy for users to discover brands, apply savings and manage their orders post-purchase, today announced it ...